BSE Sensex 30 Stocks Regulatory Filings — July 06, 2026

Standalone revenue grew 19% YoY to ₹5,666 Cr in Q1 FY27, driven by merchandise sales (+19% YoY). Store network expanded to 1,312 with net 20 new stores (19 Zudio, 1 Westside), including 7 Zudio stores in the UAE, indicating successful international expansion. No profitability data provided, but top-line momentum is strong

Consumer businesses grew 41% YoY in Q1 FY27, with jewellery portfolio buyer growth in early double-digits and average ticket sizes in high double-digits. Core jewellery categories (plain and studded) grew individually in mid-thirties, and analog watches led overall watches growth in high twenties. Added 77 net new stores, expanding retail network to 3,680

Consolidated revenue grew ~11.2% YoY to ₹584,620 million in FY26, and net profit after minority interest rose ~5.0% YoY to ₹114,794 million. Innovative Medicines business reached a new high, contributing 22% of sales and surpassing US generics in US revenue share for the first time, signaling a successful strategic shift toward higher-margin specialty drugs

Allotted ₹5,306.57 Cr in secured NCDs via private placement, with two tranches: Option I (₹4,001 Cr, 7.70% coupon, 1172-day tenure) and Option II (₹1,305 Cr, 7.79% coupon, 3651-day tenure). The successful large-scale debt raise at competitive rates indicates strong investor demand and robust credit growth outlook

Received an administrative warning letter from SEBI for insider trading violations by three connected persons (two employees and one relative) who traded while in possession of unpublished price sensitive information during July 2024. The warning cites failure to monitor trades and administer the code of conduct under SEBI (PIT) Regulations. While no financial penalty was imposed, the reputational and governance risk is significant

R&D spend as a percentage of sales declined to 6.1% from 6.2% in FY25, and revenue growth was driven more by volume and new launches than by price increases, indicating ongoing pricing pressure in the generics segment. The mixed sentiment reflects this trade-off between strategic progress and near-term headwinds

Smart Watches business declined in low teens, and Taneira (ethnic wear) growth was only in low single-digits, indicating mixed performance across segments despite strong overall growth. This divergence suggests execution challenges in newer categories

Record date for final dividend (FY2025-26) set as July 17, 2026, with AGM on August 1, 2026. The dividend payment (if declared) by August 7, 2026, provides a near-term catalyst for income-focused investors. However, no financial figures were disclosed, limiting insight into performance

Sold 13.8 crore equity shares (2.01% stake) in Jaiprakash Power Ventures Ltd through open market transactions, reducing its holding from 6.42% to 4.40%. The sale in multiple tranches by a non-promoter bank suggests a strategic exit or portfolio rebalancing, potentially signaling limited conviction in the power sector

SEBI issued an administrative warning letter for insider trading violations by three connected persons (two employees and one immediate relative) who traded in the company's scrip while in possession of unpublished price sensitive information during July 2024. The warning was addressed to the Company Secretary and Compliance Officer, citing failure to monitor trades and administer the code of conduct. This is a high-materiality (6/10) governance red flag that could lead to increased regulatory scrutiny and reputational damage

R&D spend as a percentage of sales declined to 6.1% from 6.2% in FY25, a concerning trend for a company that is pivoting toward innovative medicines. Sustained R&D investment is critical for the specialty pipeline, and any further cuts could jeopardize future growth

Revenue growth was driven more by volume and new launches than by price increases, indicating ongoing pricing pressure in the generics segment. The US generics business now accounts for a smaller share of US revenues than Innovative Medicines, reflecting this structural challenge

Smart Watches business declined in low teens, and Taneira growth was only in low single-digits, indicating execution challenges in newer categories. This divergence from the strong core jewellery and watches performance suggests potential over-diversification risk

ICICI Bank sold 2.01% of its holding in Jaiprakash Power Ventures in multiple open market tranches, reducing its stake from 6.42% to 4.40%. While the bank is not a promoter, the sale by a major financial institution could signal limited confidence in the power sector's near-term prospects

Availed a ₹5.47 Cr credit facility under ECLGS 5.0 from Axis Bank, secured by a 100% NCGTC guarantee and charge on assets. While the government-backed scheme provides liquidity, the reliance on emergency credit lines suggests working capital stress, though the company is outside the SENSEX 30 scope

No data on profitability or like-for-like store growth was provided in the Q1 FY27 update. The 19% revenue growth is driven by store expansion (20 net new stores), and without same-store sales or margin data, the quality of growth remains unverified

The final dividend for FY2025-26 is subject to approval at the AGM on August 1, 2026. While the record date (July 17) is set, the dividend amount has not been disclosed, creating uncertainty for income investors

Revenue grew 19% YoY to ₹5,666 Cr in Q1 FY27, driven by Zudio (19 of 20 new stores), including 7 stores in the UAE. Zudio's value-fashion model is scaling rapidly both domestically and internationally, and if margins are maintained, this could be a multi-year growth story. Watch for profitability data in the upcoming quarterly filing

Consumer businesses grew 41% YoY in Q1 FY27, with jewellery buyer growth in early double-digits and average ticket sizes in high double-digits. Core jewellery categories grew in mid-thirties, and analog watches in high twenties. The 77 net new stores (total 3,680) indicate aggressive retail expansion. The strong festive demand and stable gold prices create a favorable backdrop

Innovative Medicines business reached a new high, contributing 22% of consolidated sales and surpassing US generics in US revenue share for the first time. The acquisition of Organon & Co (post-FY26) will add Women's Health to the portfolio, expanding the global footprint. This strategic pivot toward higher-margin specialty drugs could drive margin expansion over the medium term

Allotted ₹5,306.57 Cr in secured NCDs with coupons of 7.70% (3.2-year) and 7.79% (10-year), indicating strong credit demand and investor confidence. The funds will likely support loan book growth, and the long-dated Option II (3651-day) provides stable funding. For fixed-income investors, these NCDs offer attractive yields relative to bank deposits

Record date for final dividend is July 17, 2026, with payment by August 7, 2026 (if declared at AGM on August 1). Investors seeking dividend income can buy before the record date, though the dividend amount is undisclosed. The AGM will also provide management commentary on Q1 performance

Board meeting scheduled for July 16, 2026, to approve Q1 FY27 results. As a recently demerged entity, ITC Hotels offers a pure-play hospitality exposure. The first quarterly result post-demerger will provide critical baseline data for valuation. Strong travel and tourism demand could drive positive surprises

Board meeting on July 29, 2026, to approve Q1 FY27 results, followed by an investor conference on the same day. Asian Paints is a bellwether for the Indian consumer discretionary sector, and the conference call will provide insights into demand trends, raw material costs, and margin outlook

Board meeting on July 18, 2026, to approve Q1 FY27 results. The bank's performance will be a key indicator for the financial sector, with focus on NIM trends, asset quality, and loan growth. The trading window reopens 48 hours after results, creating a potential entry point

Both Trent (19% YoY revenue growth) and Titan (41% YoY consumer business growth) reported robust Q1 FY27 performance, driven by festive demand, stable gold prices, and aggressive store expansion. This suggests strong consumer spending in India's discretionary segment, particularly in value retail (Zudio) and jewellery, despite global macroeconomic headwinds

Sun Pharma's FY26 results highlight a structural shift from generics to innovative medicines, with the specialty business now surpassing US generics in US revenue share. However, the slight R&D decline (6.1% vs 6.2% of sales) and pricing pressure in generics indicate the transition is not without challenges. The Organon acquisition post-FY26 could accelerate this pivot

Bajaj Finance's ₹5,306 Cr NCD issuance at 7.70%-7.79% coupons reflects strong credit demand and investor appetite for high-quality corporate debt. This contrasts with ICICI Bank's stake sale in Jaiprakash Power, suggesting selective capital deployment by banks. The financial sector is actively raising funds to support loan growth amid rising interest rates

Reliance Industries' SEBI warning for insider trading violations by connected persons is a reminder of heightened regulatory oversight under SEBI (PIT) Regulations. The warning, though administrative, signals that even India's largest conglomerate is not immune to governance lapses. This could lead to stricter compliance requirements across the board

Kotak Mahindra Bank's final dividend announcement (record date July 17) and Sun Pharma's AGM (July 31) highlight a focus on shareholder returns. However, the lack of dividend amount disclosure for Kotak and the mixed sentiment around Sun Pharma suggest that dividend growth may not keep pace with earnings growth in the current environment

Board meeting on July 16, 2026, to approve first quarterly results post-demerger. This will be a critical data point for valuing the pure-play hospitality entity. Watch for revenue per available room (RevPAR) trends and occupancy rates [July 16, 2026]

Board meeting on July 18, 2026, to approve standalone and consolidated results. Key metrics to watch: NIM, loan growth, asset quality (GNPA/NNPA), and management commentary on deposit trends. Trading window reopens 48 hours post-results [July 18, 2026]

Record date for final dividend eligibility is July 17, 2026. Investors should act before this date to qualify for the dividend. The AGM on August 1 will confirm the dividend amount [July 17, 2026]

Board meeting on July 29, 2026, followed by an investor conference. Watch for volume growth, raw material cost trends, and margin outlook. The trading window is closed until July 31, limiting insider activity visibility [July 29, 2026]

AGM on July 31, 2026, will provide management commentary on the Organon acquisition and FY26 performance. Watch for updates on integration timelines, R&D pipeline, and guidance for FY27 [July 31, 2026]

The SEBI warning letter (received July 6) could lead to further regulatory actions or enhanced compliance measures. Monitor for any subsequent filings, penalty announcements, or management responses. The stock's reaction to this governance issue will be a key sentiment indicator

The Q1 FY27 update lacked profitability metrics. Watch for the detailed quarterly filing (likely in July) for EBITDA margins, same-store sales growth, and Zudio segment profitability. This will validate the quality of the 19% revenue growth

The smart watches business declined in low teens. Watch for any strategic initiatives or product launches to revive this segment. The Q1 detailed filing will provide more granular data on segment-wise performance